Life sciences company Merck has seen an improvement in pulmonary arterial hypertension patients using its new signaling inhibitor sotatercept in a phase three clinical trial.
Sotatercept significantly increased the distance that cardiovascular patients could walk over a 24-week period. Patients in the trial also saw improvements in eight of the nine outcome measures for cardiovascular patients set by the World Health Organization.
The trial also found sotatercept reduced the risk of clinical worsening or death by 84 percent compared to a placebo, according to a March 6 press release.
Rome, Ga.-based AdventHealth Redmond has opened a cardiology center in Cedartown, Ga. AdventHealth Medical Group Cardiology at Cedartown is led…
Boynton Beach, Fla.-based Palm Beach Health Network Physician Group has added Brijeshwar Maini, MD, according to an April 16 report…
Great Falls (Mont.) Hospital Heart Center has added Randolph Hutter, MD, to its staff. Dr. Hutter is a general, noninvasive…
Comments are closed.